Hematologist
CION Cancer Clinics
Erythropoietin and luspatercept for low haemoglobin in MDS | CION Cancer Clinics
Erythropoietin (EPO) and luspatercept are injections that can raise haemoglobin and reduce how often you need blood in lower-risk MDS. EPO is usually tried first, especially when your own EPO level is low. Luspatercept is often used when EPO has not worked, particularly with ring sideroblasts. Neither treats the MDS itself, and not everyone responds. This page explains who they suit and what to expect. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What do erythropoietin and luspatercept do in MDS?
- How are EPO and luspatercept different?
- Which tests decide whether these medicines might help you?
- What happens once treatment is started?
- What side effects are possible, and who should not take them?
- What do families often believe about these injections?
- What do these words on your report mean?
- Common questions about EPO and luspatercept in MDS
The short answer
What do erythropoietin and luspatercept do in MDS?
Both are injections that help the bone marrow make more red cells, so that haemoglobin rises and you may need fewer transfusions. They are used mainly in lower-risk MDS, and they help some people well and others not at all.
Why haemoglobin falls in MDS
In MDS the marrow makes red cells, but many of them are faulty and die before they reach the blood. The result is a low haemoglobin, which shows up as tiredness, breathlessness on stairs and a pale look. Transfusions top the blood up, but they do not fix the marrow, and repeated transfusions bring their own problems, such as iron build-up.
What these medicines try to change
Erythropoietin, often shortened to EPO, is a copy of a natural hormone that tells the marrow to make red cells. Luspatercept works at a later stage. It helps young red cells finish maturing, so more of them survive into the blood. Neither medicine treats the MDS itself or changes the underlying fault in the marrow.
Your haematologist decides whether either medicine is right, sets the dose and decides when to stop. Never start, skip or stop an injection on your own.Side by side
How are EPO and luspatercept different?
Erythropoietin (EPO)
Luspatercept
Pushes the marrow to start making more red cells
Helps red cells that are already forming to mature
Usually tried first in lower-risk MDS
Often used when EPO has not worked, or is unlikely to
Works better when your own EPO level in the blood is low
Has the strongest evidence in MDS with ring sideroblasts
Injection under the skin, often weekly
Injection under the skin, spaced a few weeks apart
Generic versions are widely available in India
Newer and usually far more costly; access varies
Not sure whether this applies to you?
Ask an oncologistBefore starting
Which tests decide whether these medicines might help you?
Your haematologist looks at several results together. No single test gives a yes or no.
Your risk group
The IPSS-R or IPSS-M score sorts MDS into lower-risk and higher-risk groups. These medicines are mainly for lower-risk MDS. In higher-risk MDS, treating the disease itself usually comes first.
Your own EPO level
A blood test measures how much natural erythropoietin you already make. If it is already high, adding more is less likely to help.
The marrow report
The bone marrow biopsy report may mention ring sideroblasts, which are red cells with iron trapped in a ring around the centre.
Also looked for
- An SF3B1 gene change
- A deletion on chromosome 5q
How much blood you need
People who need fewer transfusions tend to respond better. Your team will ask for a clear record of every transfusion you have had.
The pathway
What happens once treatment is started?
-
Baseline checks
Your blood count, blood pressure, kidney tests and iron levels are recorded before the first injection, so any change can be measured against them.
-
The injections
A nurse gives the injection under the skin of the arm, thigh or belly. Some people are taught to have EPO given closer to home. The schedule is set by your haematologist.
-
A fair trial
These medicines do not work overnight. Your team usually waits for a few months before judging whether haemoglobin is rising or transfusions are becoming less frequent.
-
The review
If there is a clear benefit, treatment usually continues with regular checks. If there is none, your haematologist will stop it and discuss other options rather than continuing without purpose.
-
Ongoing watch
Even when a medicine works well, it can lose its effect over time. Regular counts show this early, so the plan can change in good time.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
What side effects are possible, and who should not take them?
Most people manage these injections without major trouble. Some side effects need watching, and a few people should not have them at all.
With erythropoietin
Blood pressure can rise, so it is checked at visits. There is a higher chance of blood clots, particularly if haemoglobin climbs too quickly. Report any new swelling or pain in one leg, chest pain or sudden breathlessness straight away.
With luspatercept
Tiredness, back or joint aches, loose motions, dizziness and a rise in blood pressure have been reported. These are often mild and may ease with time. Tell your team about anything that does not settle. Keep a short note of how you feel in the days after each injection, because it helps the team see a pattern.
Who they may not suit
They are generally not the right choice in higher-risk MDS, in people whose own EPO level is already high and who need very frequent transfusions, or in people with uncontrolled blood pressure or a recent clot. MDS with a 5q deletion is often treated differently. Pregnancy must be discussed openly before luspatercept is considered.
Commonly believed
What do families often believe about these injections?
"Once he starts the injections, he will never need blood again."
Some people stop needing transfusions for a long time. Others need fewer. Some see no change. Keep every transfusion appointment your team books until they tell you otherwise.
"The newer injection must be the stronger one, so we should ask for it first."
Newer does not mean better for you. Which medicine is likely to work depends on your EPO level, your marrow report and your risk group. For many people EPO is the sensible first step.
"Her haemoglobin went up, so the MDS is going away."
A rise in haemoglobin is a real and welcome benefit. It does not mean the MDS has changed. Regular follow-up and blood tests still matter just as much.
"EPO is what athletes misuse, so it must be dangerous."
Misuse by healthy people is a different situation. In MDS it is prescribed for a real medical need, and your team watches your blood pressure and counts to keep it safe.
On your report
What do these words on your report mean?
- Serum EPO
- The amount of natural erythropoietin in your blood. A lower level often means EPO injections have a better chance of helping.
- Ring sideroblasts
- Developing red cells with a ring of trapped iron, seen on the marrow report. Their presence can make luspatercept more likely to be discussed.
- SF3B1 mutation
- A gene change found in some MDS, often alongside ring sideroblasts. It tends to go with a lower-risk course.
- ESA
- Short for erythropoiesis-stimulating agent. It is the family name for EPO-type medicines.
- Transfusion independence
- A stretch of time with no transfusions needed. Your team uses it to judge whether a medicine is working.
Questions we are asked
Common questions about EPO and luspatercept in MDS
How soon will we know if the injection is working?
Usually not for a few months. Red cells take time to form and mature, and one good or bad count can mislead. Your haematologist watches the haemoglobin trend and how often you need blood. Reference ranges differ between laboratories, so compare results from the same lab where possible.
Can luspatercept be used if EPO did not work?
Often yes. That is one of the main situations in which it is considered, particularly when the marrow shows ring sideroblasts. In some people it is discussed as a first choice. Your haematologist will explain whether your reports make it a reasonable option.
Is luspatercept available in India?
Availability and cost can change, and supply may need to be arranged in advance. Ask your haematologist whether it is accessible for you, what it is likely to cost over several months, and what the alternatives are if it is not practical.
Can I get the injections at a clinic near my home?
Sometimes. EPO injections are simple to give, and some families arrange them closer to home once the plan is settled. Blood tests and reviews still need to happen on schedule. Discuss any arrangement with your treating team before changing where you are treated.
Do I still need iron checks while on these medicines?
Yes. If you have had many transfusions, extra iron may already have built up. Your team also needs to know your iron stores, because EPO works less well when usable iron is low. Keep your ferritin tests as planned.
Are these medicines a form of chemotherapy?
No. They do not kill cells. They support the making of red cells. Hair loss is not expected. They are also not designed to slow the MDS down, which is why higher-risk MDS is usually treated with other medicines such as azacitidine.
Will schemes or insurance pay for them?
It depends on the medicine and your cover. EPO is more often included than luspatercept. Aarogyasri, PM-JAY, CGHS, ECHS, EHS and cashless insurance each have their own rules, and those rules change. Check the current position before treatment starts.
What should we ask at the next appointment?
Ask what your risk group is, whether your EPO level has been tested, what the marrow report says about ring sideroblasts, and how the team will judge success. Ask what happens if the medicine does not work. The haematology team will explain each answer in plain words.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Supportive Therapy for Myelodysplastic Syndromes
- National Cancer Institute — Myelodysplastic Syndromes Treatment (PDQ) - Patient Version
- Leukemia & Lymphoma Society — Myelodysplastic Syndromes
- Cancer.Net — Myelodysplastic Syndromes - MDS
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Transfusion Dependence in MDSWhat regular transfusions mean for daily lifeIron Overload From Repeated TransfusionsWhy iron checks continue alongside these medicinesLower-Risk MDS: Supportive Care and MonitoringThe wider plan these injections belong toIPSS-R Risk Scoring in MDSThe score that decides whether they are offered
Talk to us
Wondering whether these injections could help?
Share your marrow report and recent blood counts. CION's haematology team will review them and explain the options. One helpline serves every CION centre.